Synthetic Biologics (SYN) Phase 2b Trial of SYN-004 for C. difficile Achieves Primary Endpoint
Tweet Send to a Friend
Synthetic Biologics, Inc. (NYSE: SYN) announced positive topline data from its Phase 2b clinical trial for SYN-004 (ribaxamase), the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
